NASDAQ: ABVCAbvc Biopharma Inc Stock
$2.33+0.07 (+3.1%)
Updated Dec 24, 2025
ABVC Price
$2.33
Fair Value Price
N/A
Market Cap
$56.62M
52 Week Low
$0.40
52 Week High
$5.48
P/E
-11.65x
P/B
4.7x
P/S
88.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$797.92k
Earnings
-$4.12M
Gross Margin
100%
Operating Margin
-507.22%
Profit Margin
-515.9%
Debt to Equity
0.55
Operating Cash Flow
-$2M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABVC Overview
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company developing drugs and medical devices derived from plants. The company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. ABVC was founded in 1990 and is headquartered in Fremont, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABVC's potential to beat the market
- ABVC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ABVC
RankedUnranked of 490
RankedUnranked of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.09 | A | |
| $19.77 | A | |
| $400.69 | A |
Be the first to know about important ABVC news, forecast changes, insider trades & much more!
ABVC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABVC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABVC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABVC is good value based on its book value relative to its share price (4.7x), compared to the US Biotechnology industry average (5.43x)
P/B vs Industry Valuation
ABVC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ABVC due diligence checks available for Premium users.
Valuation
ABVC fair value
Fair Value of ABVC stock based on Discounted Cash Flow (DCF)
Price
$2.33
Fair Value
-$2.53
Undervalued by
191.99%
ABVC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABVC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.65x
Industry
144.27x
Market
44.97x
ABVC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.7x
Industry
5.43x
ABVC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABVC's financial health
Profit margin
Revenue
$796.0k
Net Income
-$1.2M
Profit Margin
-156.6%
ABVC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ABVC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$21.2M
Liabilities
$6.7M
Debt to equity
0.55
ABVC's short-term liabilities ($6.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABVC's short-term assets ($4.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABVC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$133.3k
Investing
-$1.3M
Financing
$1.1M
ABVC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABVC vs Biotech Stocks
Abvc Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.